Literature DB >> 24680219

Abuse and diversion of buprenorphine sublingual tablets and film.

Eric J Lavonas1, S Geoffrey Severtson2, Erin M Martinez3, Becki Bucher-Bartelson4, Marie-Claire Le Lait5, Jody L Green6, Lenn E Murrelle7, Theodore J Cicero8, Steven P Kurtz9, Andrew Rosenblum10, Hilary L Surratt11, Richard C Dart12.   

Abstract

Buprenorphine abuse is common worldwide. Rates of abuse and diversion of three sublingual buprenorphine formulations (single ingredient tablets; naloxone combination tablets and film) were compared. Data were obtained from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Poison Center, Drug Diversion, Opioid Treatment (OTP), Survey of Key Informants' Patients (SKIP), and College Survey Programs through December 2012. To control for drug availability, event ratios (rates) were calculated quarterly, based on the number of patients filling prescriptions for each formulation ("unique recipients of a dispensed drug," URDD) and averaged and compared using negative binomial regression. Abuse rates in the OTP, SKIP, and College Survey Programs were greatest for single ingredient tablets, and abuse rates in the Poison Center Program and illicit diversion rates were greatest for the combination tablets. Combination film rates were significantly less than rates for either tablet formulation in all programs. No geographic pattern could be discerned.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Buprenorphine; Drug abuse; Drug formulations; Substance-related disorders

Mesh:

Substances:

Year:  2014        PMID: 24680219     DOI: 10.1016/j.jsat.2014.02.003

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  25 in total

1.  The Opioid Crisis in Missouri: A Call to Action for Physicians, Legislators, and Society.

Authors:  Lawrence Lewis; Christopher R Carpenter; Evan S Schwarz; Randall S Jotte; Corey Waller; Rachel Winograd; Randall Williams; Steven Stenger; Holly Rehder; Shannon Governick; Luis Giuffra
Journal:  Mo Med       Date:  2017 Nov-Dec

2.  A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates.

Authors:  Huiping Ding; Paul W Czoty; Norikazu Kiguchi; Gerta Cami-Kobeci; Devki D Sukhtankar; Michael A Nader; Stephen M Husbands; Mei-Chuan Ko
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-29       Impact factor: 11.205

3.  Past-year Prescription Drug Monitoring Program Opioid Prescriptions and Self-reported Opioid Use in an Emergency Department Population With Opioid Use Disorder.

Authors:  Kathryn Hawk; Gail D'Onofrio; David A Fiellin; Marek C Chawarski; Patrick G O'Connor; Patricia H Owens; Michael V Pantalon; Steven L Bernstein
Journal:  Acad Emerg Med       Date:  2017-12-26       Impact factor: 3.451

4.  Ischemic Hand Complications From Intra-Arterial Injection of Sublingual Buprenorphine/Naloxone Among Patients With Opioid Dependency.

Authors:  Ryan M Wilson; Shady Elmaraghi; Brian D Rinker
Journal:  Hand (N Y)       Date:  2016-10-03

5.  Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.

Authors:  Bradley D Stein; Rosalie Liccardo Pacula; Adam J Gordon; Rachel M Burns; Douglas L Leslie; Mark J Sorbero; Sebastian Bauhoff; Todd W Mandell; Andrew W Dick
Journal:  Milbank Q       Date:  2015-09       Impact factor: 4.911

6.  A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.

Authors:  Katharine Cioe; Breanne E Biondi; Rebecca Easly; Amanda Simard; Xiao Zheng; Sandra A Springer
Journal:  J Subst Abuse Treat       Date:  2020-09-22

7.  Patterns of non-prescribed buprenorphine and other opioid use among individuals with opioid use disorder: A latent class analysis.

Authors:  Raminta Daniulaityte; Ramzi W Nahhas; Sydney Silverstein; Silvia Martins; Angela Zaragoza; Avery Moeller; Robert G Carlson
Journal:  Drug Alcohol Depend       Date:  2019-09-22       Impact factor: 4.492

8.  Use and Misuse of Opioids in Maine: Results From Pharmacists, the Prescription Monitoring, and the Diversion Alert Programs.

Authors:  Brian J Piper; Clare E Desrosiers; John W Lipovsky; Matthew A Rodney; Robert P Baker; Kenneth L McCall; Stephanie D Nichols; Sarah L Martin
Journal:  J Stud Alcohol Drugs       Date:  2016-07       Impact factor: 2.582

9.  "You are not clean until you're not on anything": Perceptions of medication-assisted treatment in rural Appalachia.

Authors:  Emma L Richard; Christine A Schalkoff; Hannah M Piscalko; Daniel L Brook; Adams L Sibley; Kathryn E Lancaster; William C Miller; Vivian F Go
Journal:  Int J Drug Policy       Date:  2020-03-12

10.  Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.

Authors:  Rachel M Burns; Rosalie L Pacula; Sebastian Bauhoff; Adam J Gordon; Hollie Hendrikson; Douglas L Leslie; Bradley D Stein
Journal:  Subst Abus       Date:  2015-11-13       Impact factor: 3.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.